ProCE Banner Activity

CE / CME

Recent Advances in the Management of Pustular Psoriasis – Part 2

Video

Recent developments in the pathophysiologic understanding of pustular psoriasis have helped guide treatment selection and provide insights into potential therapies. In this webcast, expert faculty detail the pathophysiology behind pustular psoriasis and the differences between pustular psoriasis and plaque psoriasis as this assists with more specific and effective treatment options.

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: January 04, 2023

Expiration: January 03, 2024

No longer available for credit.

Share

Faculty

Alice Gottlieb

Alice Gottlieb, MD, PhD

Clinical Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
Medical Director
Department of Dermatology
Mount Sinai-Union Square
New York, New York

Kristine Kucera

Kristine Kucera, PA-C, MPAS, DHS

Physician Assistant
Bare Dermatology
Dallas, Texas
Adjunct Assistant Professor
UNT Health Science Center, PA Program
Ft. Worth, Texas

Provided by

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

Dermatologists and NPs, PAs, nurses, and physicians who practice in dermatology

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the pathophysiology of pustular psoriasis and how it's different from that of plaque psoriasis

Disclosure

All faculty and planners participating in continuing education activities sponsored by Clinical Care Options, LLC (CCO) and Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to CCO and PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Victoria Garcia-Albea, NP, DCNP: consultant/advisor/speaker: Sanofi-Genzyme.

Alice Gottlieb, MD, PhD: consultant/advisor: AnaptsysBio, Amgen, Avotres, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun, UCB; stock options: Xbiotech research (paid to institution): AnapytsysBio, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Novartis, Ortho, Sun, UCB.

Kristine Kucera, PA-C, MPAS, DHSc: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol-Myers Squibb, Dermavant, Leo, Novartis, Sun, UCB.

The planners and content peer reviewers from Clinical Care Options, LLC, Partners for Advancing Clinical Education, and Practicing Clinicians Exchange, do not have any relevant financial relationships to disclose, except Victoria Garcia-Albea, NP, DCNP, as noted above.

Instructions for Credit

Learners wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objective
  3. Complete evaluation form

The estimated time to complete this activity is 0.50 hours.

Format

This program has been made available online.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Clinical Care Options, LLC, Partners for Advancing Clinical Education, Practicing Clinical Exchange, or any educational supporter.

Accreditation

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

 

ANCC Credit Designation

Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit
NP course advisor: Victoria Garcia-Albea, NP, DCNP, Lahey Hospital and Medical Center, Burlington, Massachusetts

 

AAPA Credit Designation

Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until January 03, 2024. PAs should only claim credit commensurate with the extent of their participation.

 

 

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.